Latest Hospitality News

Patrys Limited is pushing forward with a proprietary injectable formulation of quetiapine targeting the lucrative delirium treatment market, leveraging a faster, lower-cost FDA 505(b)(2) regulatory pathway and strong patent protection.

Austco Healthcare’s subsidiary has locked in a decade-long maintenance contract at Jurong Health Complex, reinforcing its strategy to boost recurring revenue through long-term service agreements.

Genetic Signatures has completed a major restructure delivering $5 million in annual savings from FY2027 and secured a decade-long supply contract with Denmark’s Hvidovre Hospital, while posting $14.8 million revenue for FY2026 amid market pressures.

Global Health Limited boosted customer receipts by 12.6% to A$9.53 million for FY26, completing its SaaS platform upgrade and cutting cash burn by 30%. The company targets sustained EBITDA profitability and international expansion in FY27.

Artrya has launched its AI-powered Salix platform at Northeast Georgia Health System, marking its second U.S. commercial customer with active revenue streams from subscription and fee-per-scan models.

Vitrafy Life Sciences has partnered with the historic Hoxworth Blood Center to deploy its next-generation cryopreservation technology, aiming to address a critical gap in red blood cell preservation ahead of legacy technology discontinuation in 2027.

Alcidion delivered a record Q4 FY26 operating cashflow of $7.7 million and secured a $35 million UK contract, while completing a strategic acquisition that expands its ANZ footprint.

Entropy Neurodynamics has reported breakthrough Phase 2 clinical results for its intravenous psilocin therapy in treatment-resistant Binge Eating Disorder, alongside strong Phase 2a data in Irritable Bowel Syndrome and a new US patent filing.

Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.

Lumos Diagnostics is accelerating the rollout of its rapid FebriDx test in the US, with a top 100 urgent care group deploying across 30+ sites and three tier 1 groups validating the test across 230+ locations.

Optiscan Imaging has fast-tracked Stage 2 of its pioneering head and neck cancer imaging study, moving into live intraoperative imaging ahead of schedule. This advancement supports FDA regulatory efforts and enhances the company’s AI imaging development.

Imricor Medical Systems has submitted its final 510(k) devices to the FDA, marking a major step towards commercialising its MRI-guided cardiac catheterisation platform in the US.